{"id":"NCT00308737","sponsor":"Mannkind Corporation","briefTitle":"Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes","officialTitle":"Pulmonary Outcomes Within a 2-Year Period in Subjects With Diabetes Mellitus Treated With Technosphere /Insulin or Usual Antidiabetic Treatment and in Subjects Without Abnormalities in Glucose Control.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2008-09","completion":"2008-10","firstPosted":"2006-03-30","resultsPosted":"2014-10-16","lastUpdate":"2014-10-16"},"enrollment":2053,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes, Type 1","Diabetes, Type 2"],"interventions":[{"type":"DRUG","name":"Technosphere® Insulin Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Usual Care","otherNames":[]}],"arms":[{"label":"TI Inhalation Powder","type":"EXPERIMENTAL"},{"label":"Usual care","type":"OTHER"},{"label":"Non-diabetes","type":"NO_INTERVENTION"}],"summary":"Pulmonary Safety in Diabetics with T/I","primaryOutcome":{"measure":"Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care","timeFrame":"Baseline to Month 24","effectByArm":[{"arm":"Technosphere® Insulin","deltaMin":-0.16,"sd":0.208},{"arm":"Usual Care","deltaMin":-0.12,"sd":0.211}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":176,"countries":["United States","Canada","Czechia","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":923},"commonTop":["Hypoglycaemia","Cough","Upper respiratory tract infection","Nasopharyngitis"]}}